ImmunityBio (IBRX) Following ANKTIVA Label Expansion Still Looks Undervalued

ImmunityBio (IBRX) gained attention after the FDA expanded the label for its bladder cancer therapy ANKTIVA. The drug now covers BCG unresponsive non muscle invasive bladder cancer with papillary only tumors.

The label expansion arrives after a period of strong momentum for ImmunityBio, with the 30 day share price return at 21.74% and the year to date share price return at 390.59%. The 1 year total shareholder return of 291.70% and very large 3 year total shareholder return suggest sustained enthusiasm around the story.

Scan other high momentum biotech opportunities by reviewing our hand picked 20 high quality undiscovered gems that, like ImmunityBio, are tied to specific clinical and regulatory catalysts.

ImmunityBio now carries a very different profile to a year ago, yet prices move faster than business fundamentals. Is this surge mainly about the expanded role of ANKTIVA, or about investors crowding into the story ahead of the numbers?

Most Popular Narrative: 17% Undervalued

On the most followed view of ImmunityBio, a fair value of $12.00 sits above the recent $9.91 close, which keeps attention firmly on whether the ANKTIVA franchise and pipeline can support that gap using a 7.34% discount rate.

While the off the shelf CAR NK, m ceNK, and DNA vaccine platforms give ImmunityBio a broad oncology toolkit, these programs are still in clinical development. Any slower trial progress, manufacturing hurdles, or combination safety issues could delay the point at which they begin to contribute meaningfully to earnings.

See why 3 investors see ImmunityBio as 17% undervalued.

Result: Fair Value of $12.00 (UNDERVALUED)

Still, the ImmunityBio story can break the other way if ANKTIVA uptake lags expectations or if key trials and label reviews encounter regulatory setbacks.

Find out about the key risks to this ImmunityBio narrative.

Next Steps

If sentiment around ImmunityBio appears elevated in terms of both risk and potential reward, consider acting while the data is current and evaluate the narrative independently with 3 key rewards and 1 important warning sign.

Looking for more ImmunityBio sized opportunities?

Do not stop with ImmunityBio. Broaden your watchlist with focused stock ideas surfaced by Simply Wall Street screeners that zero in on different edges in the market.

• Target stability first by reviewing a 32 resilient stocks with low risk scores that leans on resilient balance sheets and lower volatility profiles for a smoother ride through swings.
• Hunt for value by scanning a 32 high quality undervalued stocks where quality fundamentals and pricing appear misaligned based on current metrics and financial strength.
• Spot potential early movers by filtering a 11 elite penny stocks with strong financials that already show improving financial profiles before wider attention arrives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com